



# *Limosilactobacillus fermentum* Limits *Candida glabrata* Growth by Ergosterol Depletion

Isabella Zangl,<sup>a</sup> Reinhard Beyer,<sup>a</sup> Arianna Gattesco,<sup>a</sup> Roman Labuda,<sup>b,c</sup> Ildiko-Julia Pap,<sup>d</sup> Joseph Strauss,<sup>a,c</sup> Christoph Schüller<sup>a,e</sup>

<sup>a</sup>University of Natural Resources and Life Sciences, Vienna, Institute of Microbial Genetics, Tulln, Austria

<sup>b</sup>Institute of Food Safety, Food Technology and Veterinary Public Health, University of Veterinary Medicine Vienna, Vienna, Austria

<sup>c</sup>Bioactive Microbial Metabolites, University of Natural Resources and Life Sciences, Vienna (BOKU), Institute of Microbial Genetics, Tulln, Austria

<sup>d</sup>University Hospital of St. Pölten, Institute for Hygiene and Microbiology, St. Pölten, Austria

<sup>e</sup>Core Facility Bioactive Molecules: Screening and Analysis, University of Natural Resources and Life Sciences, Vienna, Austria

**ABSTRACT** *Candida glabrata* is a human-associated opportunistic fungal pathogen. It shares its niche with *Lactobacillus* spp. in the gastrointestinal and vaginal tract. In fact, *Lactobacillus* species are thought to competitively prevent *Candida* overgrowth. We investigated the molecular aspects of this antifungal effect by analyzing the interaction of *C. glabrata* strains with *Limosilactobacillus fermentum*. From a collection of clinical *C. glabrata* isolates, we identified strains with different sensitivities to *L. fermentum* in coculture. We analyzed the variation of their expression pattern to isolate the specific response to *L. fermentum*. *C. glabrata*-*L. fermentum* coculture induced genes associated with ergosterol biosynthesis, weak acid stress, and drug/chemical stress. *L. fermentum* coculture depleted *C. glabrata* ergosterol. The reduction of ergosterol was dependent on the *Lactobacillus* species, even in coculture with different *Candida* species. We found a similar ergosterol-depleting effect with other lactobacillus strains (*Lactobacillus crispatus* and *Lactobacillus rhamnosus*) on *Candida albicans*, *Candida tropicalis*, and *Candida krusei*. The addition of ergosterol improved *C. glabrata* growth in the coculture. Blocking ergosterol synthesis with fluconazole increased the susceptibility against *L. fermentum*, which was again mitigated by the addition of ergosterol. In accordance, a *C. glabrata*  $\Delta erg11$  mutant, defective in ergosterol biosynthesis, was highly sensitive to *L. fermentum*. In conclusion, our analysis indicates an unexpected direct function of ergosterol for *C. glabrata* proliferation in coculture with *L. fermentum*.

**IMPORTANCE** The yeast *Candida glabrata*, an opportunistic fungal pathogen, and the bacterium *Limosilactobacillus fermentum* both inhabit the human gastrointestinal and vaginal tract. *Lactobacillus* species, belonging to the healthy human microbiome, are thought to prevent *C. glabrata* infections. We investigated the antifungal effect of *Limosilactobacillus fermentum* on *C. glabrata* strains quantitatively *in vitro*. The interaction between *C. glabrata* and *L. fermentum* evokes an upregulation of genes required for the synthesis of ergosterol, a sterol constituent of the fungal plasma membrane. We found a dramatic reduction of ergosterol in *C. glabrata* when it was exposed to *L. fermentum*. This effect extended to other *Candida* species and other *Lactobacillus* species. Furthermore, fungal growth was efficiently suppressed by a combination of *L. fermentum* and fluconazole, an antifungal drug which inhibits ergosterol synthesis. Thus, fungal ergosterol is a key metabolite for the suppression of *C. glabrata* by *L. fermentum*.

**KEYWORDS** *Candida glabrata*, *Lactobacillus*, candidiasis, ergosterol, microbial communities, probiotics, stress response, transcriptional regulation

*Candida glabrata* (also *Nakaseomyces glabrata*) and *Lactobacillus* spp. both belong to the human microbiome (1, 2). *C. glabrata* is part of the *Nakaseomyces* clade and is an opportunistic pathogen, which inhabits the human oral, gastrointestinal, and vaginal tract

**Editor** Slavena Vylkova, Septomics Research Center, Friedrich Schiller University and Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll Institute

**Copyright** © 2023 Zangl et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Christoph Schüller, [christoph.schueller@boku.ac.at](mailto:christoph.schueller@boku.ac.at).

The authors declare no conflict of interest.

**Received** 18 November 2022

**Accepted** 27 January 2023

(3, 4). It is the second most prevalent cause, after *Candida albicans*, of vulvovaginal candidiasis (VVC), an acute inflammatory disease of the vaginal tract (5). Despite both *Candida* spp. causing infections, *C. glabrata* is more closely related to *Saccharomyces cerevisiae* than to *C. albicans* (6).

Vulvovaginal candidiasis is traditionally treated with azoles, inhibiting the cytochrome P450 enzyme lanosterol demethylase (14 $\alpha$ -demethylase), encoded by *ERG11*, in the ergosterol biosynthesis pathway (7). Ergosterol is an essential part of the fungal cell membrane, and inhibition of the ergosterol biosynthesis pathway by azoles arrests growth (8). However, in contrast to *C. albicans*, *C. glabrata* isolates often possess intrinsic resistance against azoles (9). Resistance against azoles in *C. glabrata* is dependent partly on the overexpression of drug-exporting membrane pumps of the ABC transporter class (8).


*Lactobacillus* spp. are part of the healthy human microbiome and inhabit mainly the gut and vaginal tract (10). Whereas the gut microbiome is rather diverse, in the vaginal tract, lactobacilli are the predominant species (11). The most dominant *Lactobacillus* spp. in the vaginal tract are *Lactobacillus crispatus*, *Lactobacillus gasseri*, *Lactobacillus jensenii*, and *Lactobacillus iners* (11). Interestingly, a decrease of *L. crispatus* in combination with an increase of *L. iners* is associated with VVC (12). *Lactobacillus* spp. in general are thought to prevent *Candida* infections by reducing the adhesion of the fungus to the mucosa and producing favorable metabolites, for example, lactic acid and acetic acid, as well as enhancing the epithelial cell immune defense mechanisms (13–15). *Limosilactobacillus fermentum* (formerly *Lactobacillus fermentum* [16]) can be isolated from plants and spontaneously fermented cereals and is taken up by consumption on a regular basis. However, it is not adapted to the human gastrointestinal tract (16). Since *L. fermentum* is isolated from human feces on a regular basis, it is regarded as part of a healthy human gut microbiome (1, 16, 17). *L. fermentum* is considered a generally recognized as safe (GRAS) species and is often utilized as a probiotic. Furthermore, *L. fermentum* was shown to have an antifungal effect against *Candida albicans* and *Candida glabrata* (18, 19). *L. fermentum* is able to metabolize cholesterol (20, 21), the ergosterol equivalent of the human cell. In the human body, lactobacilli were able to regulate cholesterol content by regulating the expression of genes involved in cholesterol synthesis, metabolism, transport, and absorption (22).

The molecular mechanisms behind the *Lactobacillus*-induced antifungal effects are still unclear. The interaction of *C. albicans* with *Lactobacillus rhamnosus* (strain GG) had a global effect on virulence mechanisms, such as adhesion and change of morphology, and notably leads to downregulation of genes for ergosterol biosynthesis (23, 24). The interaction between *C. albicans* and *Lactobacillus rhamnosus* leads to decreased pathogenicity of the fungus. Pretreatment of intestinal epithelial cells with *L. rhamnosus* leads to a more hostile environment for *C. albicans*, forcing a metabolic shift, which is accompanied by a decreased virulence (25). The *C. glabrata*-*Lactobacillus* interaction has so far been linked to the mitogen-activated protein (MAP) kinase Hog1, which has a conserved role in osmotic stress response. *C. glabrata* Hog1 is involved in response to short-chain weak organic acids, such as hexadienoic acid, which is also known as sorbic acid. The pathway was found to be crucial for lactic acid response at a physiological level (110 mM) (26). *C. glabrata* Hog1 regulated the osmotic stress response pathway that is also involved in membrane homeostasis. Furthermore, the presence of *Lactobacillus* lead to a decrease of the *C. glabrata* adhesion regulating gene *YAK1* and the Yak1-dependent adhesin gene *EPA6* (27).

In this study, we investigated the interaction between *L. fermentum* and clinical *C. glabrata* isolates in coculture. We used a quantitative screening method to quantify the growth-inhibiting effect of *L. fermentum* and explored the differences between individual *C. glabrata* isolates. We analyzed the gene expression differences between clinical isolates during coculture and show that *C. glabrata* requires ergosterol biosynthesis for survival during coculture with *L. fermentum*.

## RESULTS

***Candida glabrata* isolates show phenotypic variability during coculture conditions.** *Lactobacillus* spp. exert an antifungal effect on *C. glabrata* *in vitro* (18, 28). To investigate this effect, we performed a quantitative analysis of the growth behavior of



**FIG 1** *L. fermentum* exerts an antifungal effect against *Candida glabrata*. (A) Determined CFU/mL of *Candida glabrata* and *L. fermentum* coculture versus *C. glabrata* single culture after 20 h; each data point represents at least two biological replicates ( $n = 2$  to 3), and red datapoints highlight isolates which were picked for further analysis. (B) Counted log CFU/mL of *Candida glabrata* and *L. fermentum* coculture versus counted CFU/mL of single *Candida* culture after 24 h; data represent mean log CFU/mL of at least three biological replicates ( $n = 3$  to 5). Asterisks represent a statistical difference between single and coculture conditions (\*,  $P \leq 0.05$ ). (C) *Candida glabrata* susceptibility against *L. fermentum* on MRS medium. Isolates were spotted in serial dilution onto MRS or MRS with 50  $\mu$ L of *L. fermentum* culture (OD of 1). (D) Quantitative analysis of growth performance during different conditions and stressors; data represent calculated growth rates after 24 h. Error bars represent the standard error of at least two biological replicates ( $n = 2$  to 4). Asterisks represent a statistical difference between growth rate in SD medium (=control) and growth rate during stress (\*,  $P \leq 0.05$ ).

94 *C. glabrata* isolates in coculture with *L. fermentum* (Fig. 1A). We assessed the growth performance of each strain by determining CFU/mL after 20 h of incubation in coculture and in a single-culture setting. We found that the presence of *L. fermentum* leads to a significant decrease of *Candida* growth. However, this effect is strain specific, as not all *Candida* strains were influenced to the same extent. For further analysis we chose the laboratory strain BG2 (29) and 3 clinical isolates (127P, 132P, and 122P) and counted CFU/mL after 24 h (Fig. 1B). The *C. glabrata* isolates can be grouped into


resistant (BG2 and 127P) and sensitive (122P and 132P) to *L. fermentum*. The growth performance of isolates against *L. fermentum* on solid medium revealed the same clustering as in liquid, although some growth reduction could be observed for all isolates (Fig. 1C). Next, we investigated phenotypic traits, such as general stress susceptibility of the isolates, to assess a possible connection to *L. fermentum* susceptibility (Fig. 1D). We concentrated on conditions associated with *L. fermentum* stress, for example exposure to lactic and acetic acid or low glucose levels. We quantitatively determined the growth rates of the isolates under these conditions. Strain 132P had the lowest growth rate during various stress tests. The isolates clustered in the same groups as in the *L. fermentum* sensitivity test, namely, generally lower growth rates (122P and 132P) and generally higher growth rates (BG2 and 127P) (Fig. 1C), except for growth in yeast extract-peptone (YP) medium with 2% lactate or no added carbon source, where all isolates behaved similarly. The same pattern was observed for control conditions (YP-dextrose [YPD], Sabouraud dextrose [SD], or MRS medium), which indicates an overall slower growth of 122P and 132P than that of the other two strains. H<sub>2</sub>O<sub>2</sub> stress was the only condition which led to significant growth reduction in the *L. fermentum* sensitive strains but not in the resistant *C. glabrata* isolates.

***Limosilactobacillus fermentum* causes a shift in the *Candida glabrata* transcriptome.** We used transcriptome sequencing (RNA-seq) to investigate how the presence of *L. fermentum* changes the gene expression pattern of *C. glabrata*. We compared the expression profiles of a *Candida* culture with a *L. fermentum*-*Candida* coculture after 10 h of incubation. In total, more significantly downregulated differentially expressed genes than upregulated differentially expressed genes (Fig. 2A) were detected. More differentially expressed genes were found in the two *L. fermentum*-resistant isolates (BG2 and 127P) than those in the two sensitive isolates (122P and 132P). Principal component analysis visualized the differences between the isolates (Fig. 2B). We conclude that coculture leads to a transcription shift in all *C. glabrata* isolates and is the main reason for variance (67%) in the samples. Clustering of single-culture profiles points to a similar gene expression pattern under control conditions. PC2 shows the similarity between the different isolates. However, PC2 accounts for only 12% of the total variance. Therefore, the difference of transcriptome profiles between isolates is small compared with the effect caused by different culture conditions.

Looking closer at the differences between the resistant and sensitive isolates, we found a set of genes which are repressed in the *Lactobacillus*-resistant isolates BG2 and 127P and induced in the *Lactobacillus*-sensitive isolates (Fig. 2C). Gene ontology (GO) enrichment analysis of the expression data shows genes associated with carbohydrate metabolism and energy reserve (Fig. 2C; see Table S4 in the supplemental material). Repression of energy reserve metabolism hints that the resistant isolates are not restricting growth and are less bothered by the presence of *Lactobacillus* than sensitive ones. In the induced gene set, the separation between resistant and sensitive *C. glabrata* isolates was less clear. In general, we found genes related to steroid metabolism, rRNA metabolism, and iron-sulfur cluster assembly to be upregulated (Fig. 2C; Table S4).

**Interaction with *L. fermentum* leads to the upregulation of ergosterol synthesis.** Clustering using the PathoYeasttract approach (30, 31) showed that genes regulated by transcription factors were associated with weak acid stress, drug/chemical stress, and iron limitation (Fig. 3A). Weak acid stress was to be expected since *L. fermentum* is producing acetic and lactic acid. The transcription factor *Haa1* is involved in acetic acid stress (32). The gene expression patterns of the *Haa1* regulon, as well as acetate-grown *C. glabrata*, did not reveal significant similarities to our data (see Fig. S1A and B in the supplemental material). Acetate stress may therefore be ruled out as a reason behind the transcriptome shift in coculture.

In yeast, *PDR12* is required for weak acid resistance (33–35) and is the single gene regulated by the weak acid response transcription factor War1. *CgPDR12* was upregulated in the *Lactobacillus*-resistant isolates (Fig. 3B). However, a  $\Delta pdr12$  knockout mutant was not sensitive to *L. fermentum* (Fig. 3C). Therefore, a substantial role during *Lactobacillus* interaction is unlikely for *PDR12*.




**FIG 2** Transcriptional response of four *Candida* isolates in coculture with *L. fermentum*. (A) Number of significantly up- and downregulated differentially expressed genes (DEGs) ( $P \leq 0.05$ ; minimum  $\log_2$  fold change [FC],  $\geq 1.5$ ) ( $n = 2$  to  $3$ ). (B) Principal component analysis of the isolates and conditions; strains are displayed in different colors; conditions are displayed in different shapes. (C) Heatmap for a comparison of the gene expression of the *Lactobacillus*-resistant and -sensitive isolates during coculture; data represent  $\log_2FC$  after being filtered (cutoff  $\log_2FC$ ,  $\geq 2$ ;  $P \leq 0.05$ ; and basecount,  $>20$ ), normalized, and centered. Yellow shows upregulation, blue shows downregulation, and a to c represent clusters. The GO terms table shows the most important terms in cluster; Table S4 contains the full list of GO Terms.

*Lactobacilli* are able to produce  $H_2O_2$  and thus may cause oxidative stress. Although the downregulated genes during oxidative stress overlapped with our data set, the upregulated genes were not similar (Fig. S1C). Therefore, the production of  $H_2O_2$  is unlikely to lead to the observed transcriptomic shift in gene expression.

Response to antifungal drug stress, for example azoles, often involves ergosterol synthesis. Ergosterol is an essential part of fungal cell membrane and is used as a target for antifungals. Interestingly, almost all genes of the ergosterol biosynthesis pathway were found upregulated in all *C. glabrata* isolates (see Fig. S2 in the supplemental material). Upregulated genes were related to the import and regulation of ergosterol synthesis, such as *UPC2A* and *UPC2B*, which are transcription factors responsible for sterol biosynthesis (36), *AUS1* responsible for sterol import (37), and *HES1* involved in *C. glabrata* sterol biosynthesis during azole stress (38).

Ergosterol plays a role in response to hypoxia and azole antifungals (39). The coculture setting might cause limiting oxygen availability due to the presence of *Lactobacilli* which leads to an increase of ergosterol biosynthesis. However, we think this process is unlikely because our data do not show an induction of gene sets of the general






**FIG 3** Enrichment analysis of expression data. (A) Clustering of upregulated DEG according to common transcription factor (TF) using the PathoYeasttract page; percent represents the percentage of detected DEGs in the total amount of targets of the TF. (B) Log2FC of *PDR12* during RNA-seq. Error bars represent the standard error of the logfoldchange (lfcSE) of *PDR12* ( $n = 2$  to 3). (C) Serial dilutions of BG2 and IZCG02 ( $\Delta pdr12$ ) on plates with *L. fermentum* (50  $\mu$ L OD<sub>600</sub> of 1 per plate).

hypoxia pathways derived from *S. cerevisiae* (see Fig. S3B in the supplemental material). We further found no differences in the oxygen content of the medium after 10 h of incubation and between coculture conditions and single-culture conditions (Fig. S3A), thus rejecting a potential hypoxia response in our experiment.


Azole antifungals inhibit cytochrome p450 lanosterol C14 $\alpha$  demethylase encoded by *ERG11*. Deletion of *ERG11* prevents ergosterol biosynthesis, leading to an increase of toxic sterols which are fungistatic (8). Fluconazole (FLC) treatment leads to an increase of *ERG11* expression in *C. glabrata* (40). We therefore compared the coculture expression profile data to the gene expression pattern characteristic for fluconazole treatment. Indeed, we found that the expression pattern for fluconazole stress in the strain KUE100 is very similar to the coculture profile (Fig. 4A). *C. glabrata* isolates are more resistant to fluconazole than *C. albicans* (9, 41). We determined the MIC at 50% growth inhibition (MIC<sub>50</sub>) of the isolates by measuring the optical density over time and calculating the respective growth rates (Fig. 4B). Fluconazole up to 128  $\mu$ g/mL reduced the growth rate of all isolates significantly, but it was not fungicidal. The *L. fermentum*-resistant strains BG2 and 127P had the highest resistance level with an MIC<sub>50</sub> of 32  $\mu$ g/mL fluconazole, followed by 122P (16  $\mu$ g/mL) and 132P (8  $\mu$ g/mL). Thus, the fluconazole resistance profile mirrors that seen with resistance to *L. fermentum*. Also considering the overlap in gene expression, the findings suggest effective similarities between both conditions for *C. glabrata*.

***C. glabrata* ergosterol biosynthesis is not triggered by a simple metabolite.** To evaluate the time-dependent effect of the coculture condition, we measured *ERG11* expression via quantitative PCR (qPCR) in the BG2 strain (Fig. 4C). *ERG11* expression levels peaked after 6 h and was still increased after 10 h of coincubation. After a 24-h incubation, the *ERG11* expression level was similar to untreated cultures. This finding suggests an accumulative effect due to an increased biomass of *L. fermentum* rather than an immediate stress effect. We also explored the following conditions likely caused by *L. fermentum* exposure: acetic acid, lactic acid, H<sub>2</sub>O<sub>2</sub>, acidic pH (pH 3.5), and glucose depletion (Fig. 4D). We used a 1-h treatment for the immediate effect and a 4-h treatment for the delayed effect. As expected, we found a drop in *ERG11* expression level as an immediate effect possibly due to stress-induced transient growth inhibition. After the 4-h treatment, *ERG11* expression returned to unstressed levels, suggesting that the tested conditions



**FIG 4** Fluconazole response shares similarities to *Lactobacillus* response. (A) Heatmap of expression data of mild FLC stress compared with the *Lactobacillus* response of the tested isolates; Z-scores represent log2FC scaled to the mean of the column (red, upregulation; blue, downregulation). (B) Growth rates of the *C. glabrata* isolates during different concentrations of FLC; each data point represents the mean growth rate of two biological replicates ( $n = 2$ ). (C) Expression data of *ERG11* during coculture and single culture after 2 h, 6 h, and 24 h of cultivation;  $n = 2$ . (D) Expression data of *ERG11* of BG2 treated with different stressors after 1 h (immediate response) and 4 h of treatment; supernatants were taken after 24 h of incubation; expression data were normalized to *ACT1*;  $n = 2$ .

might not play a decisive role in the upregulation of ergosterol biosynthesis. However, during coculture, a continuous mixture of stressors would be closer to the *in vivo* situation. To identify a compound or a compound mixture secreted by *L. fermentum*, we added the culture supernatant and coculture supernatant. A carbon source was added to prevent a starvation response. Both cell-free supernatants did not lead to a significant increase of *ERG11*. Taken together, we conclude from these experiments that the vicinity of living *L. fermentum* cells inhibits *C. glabrata* growth.




**FIG 5** *C. glabrata* growth in coculture is dependent on ergosterol availability. *C. glabrata* strains were stressed with *L. fermentum* and fluconazole (FLC) with and without ergosterol (4.3 µg/mL) supplementation; isolates were spotted in serial dilutions (start OD<sub>600</sub> of 1).

**Ergosterol availability is crucial for *C. glabrata* growth in coculture.** The above results suggested the possibility of a direct role of ergosterol in the *L. fermentum* *C. glabrata* coculture system. To test this possibility, we set up a coculture assay on solid medium. *L. fermentum* cells were spread out onto the plate, and *C. glabrata* was spotted onto the bacterial lawn. We added ergosterol and different concentrations of fluconazole to the medium (Fig. 5). *C. glabrata* isolates exposed to 5 µg/mL fluconazole in the presence of *L. fermentum* showed a slight decrease of growth compared with the control plate with only *L. fermentum*. Despite all isolates being resistant to 20 µg/mL fluconazole, a combination of 20 µg/mL fluconazole and *L. fermentum* abolished the growth of 122P and 132P and significantly reduced the growth of BG2 and 127P (Fig. 5). Fluconazole at a concentration of 10 µg/mL was sufficient to reduce the growth of 122P and 132P which are more sensitive to *L. fermentum*. Interestingly, the addition of ergosterol reduced the antifungal effect of *L. fermentum*.

If ergosterol is a key substance for the inhibition of *C. glabrata* and reduced ergosterol levels due to fluconazole treatment are the cause for more effective inhibition by





**FIG 6** Ergosterol content during coculture. (A) Ergosterol content of BG2 and IZCG01 ( $\Delta erg11$ ) in YPD. Data represent the average of at least two biological replicates ( $n = 2$  to  $3$ ). (B) Serial dilutions of BG2 and IZCG01 ( $\Delta erg11$ ) on  $20 \mu\text{g/ml}$  FLC or *L. fermentum* ( $50 \mu\text{L}$ ;  $\text{OD}_{600}$  of  $1$ ). (C) Measurement of the ergosterol content of single cultures of *C. albicans*, *C. krusei*, *C. tropicalis*, and *C. glabrata* (BG2) and the respective *Candida* + *L. fermentum*/*L. crispatus*/*L. rhamnosus* GG cocultures after  $10 \text{ h}$  of incubation. Data represent the mean of at least 3 biological replicates ( $n = 3$  to  $6$ ). Asterisks represent a statistical difference between single and coculture conditions (\*,  $P \leq 0.05$ ).

*L. fermentum*, an ergosterol depletion by the interruption of its biosynthesis should display a similar phenotype. We thus deleted the *ERG11* gene encoding Sterol 14-demethylase from *C. glabrata* in the BG2 background. We confirmed the knockout mutant with standard methods and show with a chemical analytical approach using a high-pressure liquid chromatography (HPLC)-based method (see Materials and Methods section) that the  $\Delta erg11$  mutant strain does not produce ergosterol (Fig. 6A). We found that this strain is unable to grow in the presence of *L. fermentum* but remains viable during fluconazole treatment (Fig. 6B). This result is in accordance with previous studies where *ERG11* knockout strains as well as a clinical isolate harboring an *ERG11* mutation showed resistance toward azoles (42, 43). Next, we asked if the ergosterol reduction is specific for the *C. glabrata*-*L. fermentum* coculture or occurs in other settings besides the already-described *C. albicans*-*L. rhamnosus* GG coculture (23, 24). We grew different *Candida* strains (*C. albicans*, *Candida tropicalis*, *Candida krusei*, and *C. glabrata*) in single-culture and coculture with different *Lactobacilli* species (*L. rhamnosus* and *L. crispatus*) and determined the ergosterol content of *Candida* cells (Fig. 6C). Importantly, we observed a significant depletion of fungal ergosterol in *L. fermentum* coculture across all tested *Candida* species. *L. crispatus*, a common vaginal *Lactobacillus* strain, significantly reduces ergosterol only in *C. krusei* and *C. glabrata*, whereas

*L. rhamnosus*, a strain often used in probiotic formulations (25, 44), was able to decrease ergosterol content only in *C. krusei* and *C. tropicalis*. We conclude that the presence of *L. fermentum* reduces *C. glabrata* ergosterol content, which probably triggers the upregulation of steroid metabolism and limits fungal growth, and that this effect is common, albeit to a various degree in other *Candida-Lactobacillus* coculture settings.

## DISCUSSION

The effect of *Lactobacillus* species on fungi is manifold and dependent on many parameters, such as species, isolate, environment, and time. To describe the general and specific aspects of these interactions, we defined quantitative *in vitro* coculture conditions, isolated highly and less sensitive *C. glabrata* strains, and selected as a suitable *Lactobacillus* strain *Limosilactobacillus fermentum* (former *Lactobacillus fermentum*). Previous studies report on the different antifungal capacities of *Lactobacillus* species against *Candida* spp. (23, 24, 45, 46). Differences in antifungal activity could be due to the various ability of different lactobacilli isolates to produce metabolic by-products like lactic acid, acetic acid, or H<sub>2</sub>O<sub>2</sub>. However, the production capacity of lactic acid and H<sub>2</sub>O<sub>2</sub> of lactobacilli does not correlate with the effectiveness against *Candida* species (45). Phenotyping of *C. glabrata* isolates did not reveal a significant correlation of stress sensitivity and growth inhibition by lactobacilli. Thus, the fungistatic effect of lactobacilli remains unclear.

To narrow down the mechanism of *C. glabrata* growth inhibition, we defined the transcriptomic response of *C. glabrata* when it was grown with *L. fermentum*. The coculture condition lead to a decrease of the adhesion-regulating gene *YAK1* and the Yak1-dependent adhesin *EPA6* in *C. glabrata* (see Table S1 in the supplemental material) in accordance with Chew (27). *Lactobacillus* spp. produce 1-acetyl  $\beta$ -carboline (1-ABC) which is linked to a reduction of filamentation via inhibition of YAK1 in *C. albicans* (47). Treatment of *C. albicans* with 1-ABC is not accompanied with a reduction in viability. Therefore, we reasoned that 1-ABC is not the reason for the antifungal effect of *L. fermentum* against *C. glabrata*. We found a gene expression pattern pointing at the involvement of an antifungal drug response pathway (Fig. 4A). Some antifungals (azoles) target the fungal plasma membrane containing ergosterol and sphingolipids (48). In accordance with that information, we found an upregulation of ergosterol biosynthesis genes in all isolates (Fig. S2). Previous studies reported that coculture of *C. albicans* and *L. rhamnosus* GG leads to a decrease in ergosterol content in the plasma membrane, as well as a downregulation of ergosterol biosynthesis (23, 24). Mailänder-Sánchez (24) analyzed the ergosterol content of the *C. albicans* and *L. rhamnosus* GG coculture on epithelial cells. In contrast to the findings of Mailänder-Sánchez, in our experimental setting, a coculture with *L. rhamnosus* did not lead to a significant ergosterol reduction in *C. albicans* but did in *C. tropicalis* and *C. krusei*. The reduction of ergosterol in the *Candida* cell membrane varied between different *Lactobacillus* species. Coculture with *L. fermentum* was the most effective, leading to a dramatic decrease of ergosterol in the fungal cell membrane of *C. glabrata*, as well as all other tested *Candida* species (Fig. 6C). We assume that this effect is probably triggering the upregulation of ergosterol synthesis. If ergosterol plays a direct role, a strain with compromised biosynthesis would possibly be hypersensitive to *L. fermentum* exposure. We generated a  $\Delta erg11$  strain in the BG2 strain background. The  $\Delta erg11$  strain, which cannot produce ergosterol, was indeed unable to grow in the presence of *L. fermentum*. *L. fermentum* is able to metabolize cholesterol (20), which is structurally similar to ergosterol. If *L. fermentum* is able to metabolize ergosterol too, it could lead to the decrease in ergosterol content during coculture.


In *C. albicans*, lactate as a carbon source leads to a lower expression of *CaERG11* and *CaERG3* and is accompanied by a reduction of ergosterol content in the plasma membrane (49). Lactobacilli in general produce lactic acid during homolactic fermentation (50). *ERG11* encodes a key enzyme of the ergosterol pathway and is regulated according to the demand of ergosterol biosynthesis. We found that *CgERG11* was upregulated during coculture but transiently downregulated in the presence of lactic acid after 1 h of treatment and returned to normal after 4 h (Fig. 4D). Therefore, in

*C. glabrata*, lactic acid is unlikely a main player in the *L. fermentum*-dependent reduction of ergosterol. It is possible that *C. albicans*, unlike *C. glabrata*, lacks the response to compensate for *Lactobacillus*-induced downregulation of ergosterol synthesis and ergosterol content. This finding could explain the higher susceptibility of *C. albicans* isolates (compared with that of *C. glabrata*) to the fungistatic effect of *Lactobacillus* spp.

*C. glabrata* gene response pattern in coculture with *L. fermentum* shares similarities to mild FLC stress (51), hinting at a similar response pathway for both conditions. Strains BG2 and 127P had an MIC<sub>50</sub> of 32 µg/mL to fluconazole, whereas 122P and 132P had lower MIC<sub>50</sub> values (16 µg/mL and 8 µg/mL, respectively). BG2 is a clinical isolate known to be unresponsive to FLC treatment (29). FLC-resistant isolates BG2 and 127P were also more resistant to *L. fermentum*, which further hints to an overlap of fluconazole and *L. fermentum* response. Previous studies report that a combination of *Lactobacillus* and azole treatment was more effective at reducing *C. albicans* and *C. glabrata* burden than azole treatment alone in *in vivo* and *in vitro* (52–54). We confirm that the combination of fluconazole and *L. fermentum* decreases the growth of *C. glabrata* much more efficiently than fluconazole or lactobacilli treatment alone. Lourenço et al. (55) showed that 60 mM acetic acid at a low pH reduces resistance against FLC. The production of acetate was one of the main differences between effective and ineffective lactobacilli; however, concentrations around  $4.6 \pm 0.5$  mM were measured (28). Compared with the data of Lourenço et al. (55), it would be too low to exert the combinational effect of acetic acid and FLC toward *C. glabrata*. In conclusion, we suggest that acetic acid does not play a major role in the combinational effect of FLC and lactobacilli. Taken together, the unavailability of ergosterol, either by fluconazole blocking ergosterol synthesis or by mutation, makes *C. glabrata* isolates more susceptible toward the effects of *L. fermentum*.

If ergosterol deprivation is a key determinant of *C. glabrata* inhibition by *L. fermentum*, the supplementation of the medium with ergosterol would likely support *C. glabrata* growth, which was indeed the case. *C. glabrata* can import sterols under aerobic and anaerobic conditions (56). It was shown that the presence of sterol can mitigate the effect of fluconazole in sterol-synthesis-defective mutants (38). The sterol transporter protein CgAus1 mediates sterol uptake (57). In addition, *ERG25* is needed for proper sterol uptake and helps to stabilize sterol-rich lipid domains in the cell membrane (58). However, in an aerobic environment, *C. glabrata* takes up sterols only during iron limitation conditions (57). It was also shown that iron limitation but not fluconazole stress leads to upregulation of *CgAUS1* (57). Furthermore, iron availability was linked to lower Erg11 activity and may subsequently reduce ergosterol content (59). We show here that the presence of *L. fermentum* leads to the upregulation of *CgAUS1* in all four tested isolates, as well as reduced ergosterol content. Additionally, genes regulated by Aft2, a transcription factor responsible for iron homeostasis in *S. cerevisiae*, were found upregulated under coculture conditions (Fig. 3A) (60). This result could hint at an involvement of the iron homeostasis system during coculture, which enables the import of sterols.

The antifungal effect of *Lactobacillus* spp. toward *C. glabrata* is not fully understood. It is currently unclear what leads to a depletion of ergosterol and subsequent growth inhibition of *C. glabrata* if ergosterol cannot be replenished. The antifungal effect of *L. fermentum* varies substantially between different *C. glabrata* isolates. The common transcriptional response of the different isolates clearly revealed steroid biosynthesis as a key factor. However, the strain-specific transcriptional patterns did not allow us to deduce the basis of individual phenotypic differences. A further thorough exploration of the genomes of our *Candida* isolates could help to understand the genetic basis of the observed phenotypic differences. To our knowledge, we are the first to show that interactions between *L. fermentum* and *C. glabrata* lead to a lower ergosterol content in the fungal cell and upregulation of genes for sterol biosynthesis and import. The antifungal effect of *L. fermentum* can be enhanced by blocking ergosterol biosynthesis with azoles and reduced by ergosterol supplementation (Fig. 7). Finally, we regard the ergosterol depletion effect of *Candida* by *Lactobacillus* as strikingly common. These



**FIG 7** Schematic overview of the interaction between *L. fermentum* and *C. glabrata*. *Lactobacillus* leads to reduced growth, due to a decrease of ergosterol availability for *C. glabrata*.

results suggest direct communication between the two species, and it is interesting to note that the bacterium is exploiting the same fungal molecular Achilles heel as conventional antifungal drugs.

MATERIALS AND METHODS

**Microbial strains and culture conditions.** This study used the clinical isolate BG2 (29) and 93 clinical *C. glabrata* isolates, as well as *C. albicans*, *C. krusei*, and *C. tropicalis* isolates, which were collected and provided by the Institute of Hygiene and Microbiology at University Hospital St. Pölten. They were propagated in YPD medium at 37°C and 180 rpm. *Limosilactobacillus fermentum* and *L. crispatus* were collected and provided by the General Hospital of Vienna. *L. rhamnosus* (ATCC 53103) was purchased. Standard culture was performed in MRS medium at 37°C and 80 rpm.

**Strain construction.** A BG2 strain deleted for *ERG11* (IZCG01  $\Delta$ *erg11::NAT1*) was generated. Flanking regions (500 bp) of *ERG11* (CAGL0E04334g) were amplified from the genomic DNA of BG2. *NAT1* was amplified from plasmid pV1382 (Addgene plasmid number 111436; <http://n2t.net/addgene> number 111436; RRID:Addgene\_111436) (61). The fragments were joined using the primer pair IZ1 and IZ4. The resulting fragment was transformed into BG2 via a heat shock method described previously (62) using ClonNAT (Sigma-Aldrich) as positive selection. Clones were screened for the correct insert using primers IZ\_col\_erg\_F and IZ\_col\_erg\_R.

A BG2 strain deleted for *PDR12* (IZGC02  $\Delta$ *pdr12*) was generated via CRISPR-Cas9 using the a method described previously (61). The plasmid pV1326 (Addgene plasmid number 111435; <http://n2t.net/addgene> number 111435; RRID:Addgene\_111435) was used (61). A single guide RNA was designed using CHOPCHOP v3 (63). ClonNAT (Sigma-Aldrich) was used as the positive selection. All oligonucleotides used in this study are listed in Table 1.

**Liquid coculture assay.** An overnight culture of *C. glabrata* was diluted to an optical density at 600 nm (OD<sub>600</sub>) of 0.1 into MRS containing *L. fermentum* at an OD<sub>600</sub> of 0.05. Single cultures with only *Candida* were used as the control. Cultures were incubated at 37°C and 80 rpm for 10 h. Serial dilutions

**TABLE 1** List of oligonucleotides used in this study

Name	Sequence (5'–3')	Description
IZ1	CGATTGTATCGGACAAATCG	ERG11_flank1_F
IZ2	GACGAGGCAAGCTTGATGCCAAAATTGCAGTTTGTTAAGGG	ERG11_flank1_R + overhang NAT1
IZ3	GAT TTG ATA CTA ACG CCG CCA AGG TTC ATA GCC ATA TTC TGG	ERG11_flank2_F + overhang NAT1
IZ4	GGAAGATCATATTGAATCTGG	ERG11_flank2_R
IZ_col_erg_F	CGA CTA CTT CAA GGC TAT TTG	Colony PCR deltaERG11
IZ_col_erg_R	GTA AAC TTC GCC TCC AGA AA	Colony PCR deltaERG11
IZ_nat_F	CTT GGC GGC GTT AGT ATC AAA TCG	NAT1 gene amplification
IZ_nat_R	CAA AGA GCG GCC GCA TCA AGC TTG	NAT1 gene amplification
pdr12_guide1_F	GAT CGA GTT ATC TCC ACC AAG ACA AG	Single guide RNA for CRISPR/Cas
pdr12_guide1_R	AAA ACT TGT CTT GGT GGA GAT AAC TC	Single guide RNA for CRISPR/Cas
pdr12_check1_F	AGC AAT GTT GAG CAA CCA GC	Colony PCR deltaPDR12
pdr12_check1_R	AAG GAA AGG AAG GAT GAT GC-	Colony PCR deltaPDR12

were plated onto YPD supplemented with 50 µg/mL ampicillin. CFUs were counted the next day, and log CFU/mL was calculated.

**Spotting assay.** Overnight cultures of *C. glabrata* were regrown until an OD<sub>600</sub> of 1. Spots (2 µL) of a serial dilution (1:10) were spotted onto MRS, onto which 50 µL of *L. fermentum* (OD<sub>600</sub> of 1) was spread previously. Up to 20 µg/ml Fluconazole was added to the MRS medium. For ergosterol supplementation, 4 µg/ml ergosterol (Sigma-Aldrich) was added to the medium. Plates were incubated and inspected every day for up to 6 days.

**RNA extraction.** RNA extraction was done by glass bead disruption and phenol-chloroform extraction as described earlier from a 30-mL culture in 200 µL extraction buffer (50 mM Tris [pH 7], 130 mM NaCl, 5 mM EDTA, and 5% SDS) and 200 µL phenol-chloroform-isoamylalcohol (25:24:1; Carl Roth GmbH, Germany). The upper aqueous layer was extracted twice with chloroform-isoamylalcohol (24:1), and the RNA was precipitated with EtOH/NaAcetate, washed and dried, and resuspended in 50 µL RNase-free water.

**Library preparation, sequencing, and differential gene expression analysis.** Library preparation and sequencing were performed by the Next Generation Sequencing Facility at Vienna BioCenter Core Facilities (VBCF), a member of the Vienna BioCenter (VBC), Austria. PolyA enrichment library preparation and single-read sequencing (50 bp, Illumina HiSeqV4) were obtained of BG2, 122P, 127P, and 132P with and without *L. fermentum*. At least 2 biological replications of each sample were sequenced and used for subsequent analysis. Demultiplexing was performed by VBCF NGS with bcl2fastq v2.20.0.422. Quality control was performed using FastQC. Reads were aligned against the *C. glabrata* CBS138 reference genome, which was obtained from the *Candida* Genome Database (CGD; <http://www.candidagenome.org>), using Bowtie 2 (64). Quantification of the aligned reads was performed with Rsubread (65) with default settings. Identification of differentially expressed genes (DEGs) between single culture and coculture of each isolate was done using R package DESeq2 (66) with default parameters. Arbitrary cutoff values for DEGs ( $P \leq 0.05$  and log<sub>2</sub> fold change of  $\geq 1.5$ ) were chosen. GO term enrichment analysis for the category “metabolic process” was performed using the database of CGD with default settings. Clustering according to transcription factor (TF) was performed using the database of PathoYeasttract (<http://pathoyeasttract.org>). Only documented entries were used for “search by TF.”

**Phenotypic stress test and MIC assay.** Overnight cultures of *C. glabrata* were regrown in YPD, SD full (yeast nitrogen base without amino acids supplemented with ammonium sulfate; BD Difco USA), or MRS medium up to an OD<sub>600</sub> of ~0.5 and diluted 1:10 into the respective medium in a 96-well flat-bottom plate. Stress tests with L-lactic acid (Carl Roth GmbH, Germany), acetic acid (Carl Roth GmbH), H<sub>2</sub>O<sub>2</sub> (Carl Roth GmbH), and at pH 4 and pH 8 were done in SD full medium. For lactic acid and acetic acid, pH was adjusted to pH 4 with HCl; 2% L-lactate (wt/vol) as a carbon source was used in SD full medium, with the pH adjusted to pH 4 with HCl. For every tested condition, *C. glabrata* isolates were incubated at 37°C in at least triplicates and OD<sub>600</sub> was monitored with an automated set-up (Cytomat42 [Thermo Fisher Scientific, MA, USA], Synergy 95 H1 [Agilent, USA], and Rack Runner 720 [Hamilton Robotics, Germany]). An MIC assay with FLC (0.125 to 256 mg/L) was performed in SD full medium. *C. glabrata* cells were inoculated with an OD<sub>600</sub> of ~0.05 and incubated at 37°C. The OD<sub>600</sub> was monitored in 2-h intervals for 24 h with a fully automated set-up.

**Ergosterol quantification.** For the extraction of ergosterol content, the isolates were grown in MRS until an OD<sub>600</sub> of 40 was reached. Coculture samples were separated by centrifugation (2,000 rpm for 5 min). The quantification method was described previously (67). In short, pellets were resuspended with 250 µL 10% (wt/wt) KOH in MeOH, followed by sonication (15 min) and 70°C for 50 min. A total of 50 µL HPLC-grade water and 100 µL n-hexane (Merck, Germany) were added, and the phases were separated by centrifugation. The hydrophobic upper phase was collected followed by a second extraction step. n-Hexane was evaporated at 40°C. When it was completely dry, 100 µL MeOH (Merck, Germany) was added and incubated for 15 min at 40°C. Ergosterol was determined via C<sub>18</sub> reverse phase using HPLC (1200 Series; Agilent Technologies, USA), and detection was performed at 282 nm, a column temperature of 25°C, an isocratic elution of 95% MeOH, and a 5% H<sub>2</sub>O flow rate of 0.3 mL min<sup>-1</sup>. The retention time of ergosterol was 3.9 min. Ergosterol content was calculated using a standard curve. Ergosterol content is stated as µg per mL extraction volume.

**Statistical analysis.** Growth rates for the MIC assay and phenotypic stress tests were calculated using the “growthcurver” package in R (68, 69). A heatmap for Fig. 2 was prepared using cluster 3.0 (70) and Java Treeview (71). Clustering for this heatmap was done using complete linkage clustering and correlation as a similarity metric. Other heatmaps were generated using the R package “pheatmap.” The genes used for diverse heatmaps are listed in Table S2 in the supplemental material. The principal component analysis was performed and displayed using DESeq2. Dot plots were generated using ggplot2 (72).

**Data availability.** Raw RNA sequencing data were uploaded to the Gene Expression Omnibus (GEO) under accession number [GSE202656](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE202656).

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**SUPPLEMENTAL FILE 1**, XLSX file, 2.8 MB.

**SUPPLEMENTAL FILE 2**, XLSX file, 0.2 MB.

**SUPPLEMENTAL FILE 3**, XLSX file, 0.04 MB.

**SUPPLEMENTAL FILE 4**, XLSX file, 0.1 MB.

**SUPPLEMENTAL FILE 5**, PDF file, 0.8 MB.



## ACKNOWLEDGMENTS

The work was supported by grants from the Gesellschaft für Forschungsförderung Niederösterreich m.b.H. GFF LSC2016-16 and LSC2013-16 to C.S. and from ChroCosm P 32790 FWF to J.S. The grants from the Gesellschaft für Forschungsförderung Niederösterreich m.b.H. GFF were awarded and the work supervised in collaboration with the late Christoph Aspöck, who was head of the Institute of Hygiene and Microbiology at University Hospital St. Pölten.

We acknowledge the contribution of the Core Facility Bioactive Microbial Metabolites: Screening and Analysis (CF BMoSA) of the University of Natural Resources and Life Sciences, Vienna. The Bioactive Microbial Metabolites facility (BiMM) is supported by grants of the Niederösterreichische Forschungs- und Bildungsges.m.b.H (NfB) (K3-G-2/026-2013) and K3-G-2/081-2020 to J.S.

## REFERENCES

- Rossi M, Martínez-Martínez D, Amaretti A, Ulrici A, Raimondi S, Moya A. 2016. Mining metagenomic whole genome sequences revealed subdominant but constant *Lactobacillus* population in the human gut microbiota. *Environ Microbiol Rep* 8:399–406. <https://doi.org/10.1111/1758-2229.12405>.
- Pérez JC. 2021. Fungi of the human gut microbiota: roles and significance. *Int J Med Microbiol* 311:151490. <https://doi.org/10.1016/j.jjmm.2021.151490>.
- Kurtzman CP. 2003. Phylogenetic circumscription of *Saccharomyces*, *Kluyveromyces* and other members of the *Saccharomycetaceae*, and the proposal of the new genera *Lachancea*, *Nakaseomyces*, *Naumovia*, *Vanderwaltozyma* and *Zygorulasporea*. *FEMS Yeast Res* 4:233–245. [https://doi.org/10.1016/S1567-1356\(03\)00175-2](https://doi.org/10.1016/S1567-1356(03)00175-2).
- Huffnagle GB, Noverr MC. 2013. The emerging world of the fungal microbiome. *Trends Microbiol* 21:334–341. <https://doi.org/10.1016/j.tim.2013.04.002>.
- Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM, Lockhart SR, Park BJ. 2015. Declining incidence of candidemia and the shifting epidemiology of *Candida* resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance. *PLoS One* 10:e0120452. <https://doi.org/10.1371/journal.pone.0120452>.
- Gabalón T, Carreté L. 2016. The birth of a deadly yeast: tracing the evolutionary emergence of virulence traits in *Candida glabrata*. *FEMS Yeast Res* 16:fov110. <https://doi.org/10.1093/femsyr/fov110>.
- Hitchcock CA. 1991. Cytochrome P-450-dependent 14 $\alpha$ -sterol demethylase of *Candida albicans* and its interaction with azole antifungals. *Biochem Soc Trans* 19:782–787. <https://doi.org/10.1042/bst0190782>.
- Berkow E, Lockhart S. 2017. Fluconazole resistance in *Candida* species: a current perspective. *Infect Drug Resist* 10:237–245. <https://doi.org/10.2147/IDR.S118892>.
- Beyer R, Spettel K, Zeller I, Lass-Flörl C, Achleitner D, Krause R, Apfalter P, Buzina W, Strauss J, Gregori C, Schüller C, Willinger B. 2019. Antifungal susceptibility of yeast bloodstream isolates collected during a 10-year period in Austria. *Mycoses* 62:357–367. <https://doi.org/10.1111/myc.12892>.
- Lloyd-Price J, Abu-Ali G, Huttenhower C. 2016. The healthy human microbiome. *Genome Med* 8:51. <https://doi.org/10.1186/s13073-016-0307-y>.
- Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ. 2011. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* 108:4680–4687. <https://doi.org/10.1073/pnas.1002611107>.
- McCloud E, Delaney C, Sherry L, Kean R, Williams S, Metcalfe R, Thomas R, Richardson R, Gerasimidis K, Nile CJ, Williams C, Ramage G. 2021. Recurrent vulvovaginal candidiasis: a dynamic interkingdom biofilm disease of *Candida* and *Lactobacillus*. *mSystems* 6:e00622-21. <https://doi.org/10.1128/mSystems.00622-21>.
- Morais IMC, Cordeiro AL, Teixeira GS, Domingues VS, Nardi RMD, Monteiro AS, Alves RJ, Siqueira EP, Santos VL. 2017. Biological and physicochemical properties of biosurfactants produced by *Lactobacillus jensenii* P6A and *Lactobacillus gasserii* P65. *Microb Cell Fact* 16:155. <https://doi.org/10.1186/s12934-017-0769-7>.
- Schaller M, Boeld U, Oberbauer S, Hamm G, Hube B, Kortling HC. 2004. Polymorphonuclear leukocytes (PMNs) induce protective Th1-type cytokine epithelial responses in an *in vitro* model of oral candidosis. *Microbiology (Reading)* 150:2807–2813. <https://doi.org/10.1099/mic.0.27169-0>.
- Vazquez-Munoz R, Dongari-Bagtzoglou A. 2021. Anticandidal activities by *Lactobacillus* species: an update on mechanisms of action. *Front Oral Health* 2:689382. <https://doi.org/10.3389/froh.2021.689382>.
- Duar RM, Lin XB, Zheng J, Martino ME, Grenier T, Pérez-Muñoz ME, Leulier F, Gänzle M, Walter J. 2017. Lifestyles in transition: evolution and natural history of the genus *Lactobacillus*. *FEMS Microbiol Rev* 41:S27–S48. <https://doi.org/10.1093/femsre/fux030>.
- Zheng J, Wittouck S, Salvetti E, Franz CMAP, Harris HMB, Mattarelli P, O'Toole PW, Pot B, Vandamme P, Walter J, Watanabe K, Wuyts S, Felis GE, Gänzle MG, Lebeer S. 2020. A taxonomic note on the genus *Lactobacillus*: description of 23 novel genera, emended description of the genus *Lactobacillus* Beijerinck 1901, and union of *Lactobacillaceae* and *Leuconostocaceae*. *Int J Syst Evol Microbiol* 70:2782–2858. <https://doi.org/10.1099/ijsem.0.004107>.
- do Carmo MS, Noronha FMF, Arruda MO, Costa ÉPdS, Bomfim MRQ, Monteiro AS, Ferro TAF, Fernandes ES, Girón JA, Monteiro-Neto V. 2016. *Lactobacillus fermentum* ATCC 23271 displays *in vitro* inhibitory activities against *Candida* spp. *Front Microbiol* 7:1722. <https://doi.org/10.3389/fmicb.2016.01722>.
- Deidda F, Amoroso A, Nicola S, Graziano T, Pane M, Allesina S, et al. 2016. The *in vitro* effectiveness of *Lactobacillus fermentum* against different *Candida* species compared with broadly used azoles. *J Clin Gastroenterol* 50:S171–S174. <https://doi.org/10.1097/MCG.0000000000000686>.
- Pereira DIA, Gibson GR. 2002. Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. *Appl Environ Microbiol* 68:4689–4693. <https://doi.org/10.1128/AEM.68.9.4689-4693.2002>.
- Mikelsaar M, Zilmer M. 2009. *Lactobacillus fermentum* ME-3—an antimicrobial and antioxidative probiotic. *Microb Ecol Health Dis* 21:1–27. <https://doi.org/10.1080/08910600902815561>.
- Cao K, Zhang K, Ma M, Ma J, Tian J, Jin Y. 2021. *Lactobacillus* mediates the expression of NPC1L1, CYP7A1, and ABCG5 genes to regulate cholesterol. *Food Sci Nutr* 9:6882–6891. <https://doi.org/10.1002/fsn3.2600>.
- Köhler GA, Assefa S, Reid G. 2012. Probiotic interference of *Lactobacillus rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14 with the opportunistic fungal pathogen *Candida albicans*. *Infect Dis Obstet Gynecol* 2012:636474. <https://doi.org/10.1155/2012/636474>.
- Mailänder-Sánchez D, Braunsdorf C, Grumaz C, Müller C, Lorenz S, Stevens P, Wagener J, Hebecker B, Hube B, Bracher F, Sohn K, Schaller M. 2017. Antifungal defense of probiotic *Lactobacillus rhamnosus* GG is mediated by blocking adhesion and nutrient depletion. *PLoS One* 12:e0184438. <https://doi.org/10.1371/journal.pone.0184438>.
- Alonso-Roman R, Last A, Mirhakkak MH, Sprague JL, Möller L, Großmann P, Graf K, Gratz R, Mogavero S, Vylkova S, Panagiotou G, Schäuble S, Hube B, Gresnigt MS. 2022. *Lactobacillus rhamnosus* colonisation antagonizes *Candida albicans* by forcing metabolic adaptations that compromise pathogenicity. *Nat Commun* 13:3192. <https://doi.org/10.1038/s41467-022-30661-5>.
- Beyer R, Jandric Z, Zutz C, Gregori C, Willinger B, Jacobsen ID, Kovarik P, Strauss J, Schüller C. 2018. Competition of *Candida glabrata* against *Lactobacillus* is Hsp91 dependent. *Cell Microbiol* 20:e12943. <https://doi.org/10.1111/cmi.12943>.
- Chew SY, Cheah YK, Seow HF, Sandai D, Than LTL. 2015. *In vitro* modulation of probiotic bacteria on the biofilm of *Candida glabrata*. *Anaerobe* 34:132–138. <https://doi.org/10.1016/j.anaerobe.2015.05.009>.

28. Parolin C, Croatti V, Laghi L, Giordani B, Tondi MR, De Gregorio PR, Foschi C, Vitali B. 2021. *Lactobacillus* biofilms influence anti-*Candida* activity. *Front Microbiol* 12:750368. <https://doi.org/10.3389/fmicb.2021.750368>.
29. Cormack BP, Falkow S. 1999. Efficient homologous and illegitimate recombination in the opportunistic yeast pathogen *Candida glabrata*. *Genetics* 151:979–987. <https://doi.org/10.1093/genetics/151.3.979>.
30. Monteiro PT, Oliveira J, Pais P, Antunes M, Palma M, Cavalheiro M, Galocha M, Godinho CP, Martins LC, Bourbon N, Mota MN, Ribeiro RA, Viana R, Sá-Correia I, Teixeira MC. 2020. YEASTRACT+: a portal for cross-species comparative genomics of transcription regulation in yeasts. *Nucleic Acids Res* 48:D642–D649. <https://doi.org/10.1093/nar/gkz859>.
31. Monteiro PT, Pais P, Costa C, Manna S, Sá-Correia I, Teixeira MC. 2017. The PathoYeast database: an information system for the analysis of gene and genomic transcription regulation in pathogenic yeasts. *Nucleic Acids Res* 45:D597–D603. <https://doi.org/10.1093/nar/gkw817>.
32. Bernardo RT, Cunha DV, Wang C, Pereira L, Silva S, Salazar SB, Schröder MS, Okamoto M, Takahashi-Nakaguchi A, Chibana H, Aoyama T, Sá-Correia I, Azeredo J, Butler G, Mira NP. 2017. The CgHaa1-regulon mediates response and tolerance to acetic acid stress in the human pathogen *Candida glabrata*. *G3 (Bethesda)* 7:1–18. <https://doi.org/10.1534/g3.116.034660>.
33. Jandric Z, Gregori C, Klopff E, Radolf M, Schüller C. 2013. Sorbic acid stress activates the *Candida glabrata* high osmolarity glycerol MAP kinase pathway. *Front Microbiol* 4:350. <https://doi.org/10.3389/fmicb.2013.00350>.
34. Schüller C, Mammun YM, Mollapour M, Krapf G, Schuster M, Bauer BE, Piper PW, Kuchler K. 2004. Global phenotypic analysis and transcriptional profiling defines the weak acid stress response regulon in *Saccharomyces cerevisiae*. *Mol Biol Cell* 15:706–720. <https://doi.org/10.1091/mbc.e03-05-0322>.
35. Kren A, Mammun YM, Bauer BE, Schüller C, Wolfger H, Hatzixanthos K, Mollapour M, Gregori C, Piper P, Kuchler K. 2003. War1p, a novel transcription factor controlling weak acid stress response in yeast. *Mol Cell Biol* 23:1775–1785. <https://doi.org/10.1128/MCB.23.5.1775-1785.2003>.
36. Nagi M, Nakayama H, Tanabe K, Bard M, Aoyama T, Okano M, Higashi S, Ueno K, Chibana H, Niimi M, Yamagoe S, Umeyama T, Kajiwara S, Ohno H, Miyazaki Y. 2011. Transcription factors *CgUPC2A* and *CgUPC2B* regulate ergosterol biosynthetic genes in *Candida glabrata*. *Genes Cells* 16:80–89. <https://doi.org/10.1111/j.1365-2443.2010.01470.x>.
37. Nakayama H, Tanabe K, Bard M, Hodgson W, Wu S, Takemori D, Aoyama T, Kumaraswami NS, Metzler L, Takano Y, Chibana H, Niimi M. 2007. The *Candida glabrata* putative sterol transporter gene *CgAUS1* protects cells against azoles in the presence of serum. *J Antimicrob Chemother* 60:1264–1272. <https://doi.org/10.1093/jac/dkm321>.
38. Li QQ, Tsai HF, Mandal A, Walker BA, Noble JA, Fukuda Y, Bennett JE. 2018. Sterol uptake and sterol biosynthesis act coordinately to mediate antifungal resistance in *Candida glabrata* under azole and hypoxic stress. *Mol Med Rep* 17:6585–6597. <https://doi.org/10.3892/mmr.2018.8716>.
39. Ernst JF, Tielker D. 2009. Responses to hypoxia in fungal pathogens. *Cell Microbiol* 11:183–190. <https://doi.org/10.1111/j.1462-5822.2008.01259.x>.
40. Vu BG, Thomas GH, Moye-Rowley WS. 2019. Evidence that ergosterol biosynthesis modulates activity of the Pdr1 transcription factor in *Candida glabrata*. *mBio* 10:e00934-19. <https://doi.org/10.1128/mBio.00934-19>.
41. Pfaller MA, Rhomberg PR, Messer SA, Jones RN, Castanheira M. 2015. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. *Diagn Microbiol Infect Dis* 82:303–313. <https://doi.org/10.1016/j.diagmicrobio.2015.04.008>.
42. Geber A, Hitchcock CA, Swartz JE, Pullen FS, Marsden KE, Kwon-Chung KJ, Bennett JE. 1995. Deletion of the *Candida glabrata* *ERG3* and *ERG11* genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. *Antimicrob Agents Chemother* 39:2708–2717. <https://doi.org/10.1128/AAC.39.12.2708>.
43. Hull CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AGS, Kelly DE, Kelly SL. 2012. Facultative sterol uptake in an ergosterol-deficient clinical isolate of *Candida glabrata* harboring a missense mutation in *ERG11* and exhibiting cross-resistance to azoles and amphotericin B. *Antimicrob Agents Chemother* 56:4223–4232. <https://doi.org/10.1128/AAC.06253-11>.
44. Capurso L. 2019. Thirty years of *Lactobacillus rhamnosus* GG: a review. *J Clin Gastroenterol* 53:S1–S41. <https://doi.org/10.1097/MCG.0000000000001170>.
45. Parolin C, Marangoni A, Laghi L, Foschi C, Palomino RAN, Calonghi N, et al. 2015. Isolation of vaginal *Lactobacilli* and characterization of anti-*Candida* activity. *PLoS One* 10:e0131220. <https://doi.org/10.1371/journal.pone.0131220>.
46. Spaggiari L, Sala A, Ardizzoni A, De Seta F, Singh DK, Gacser A, et al. 2022. *Lactobacillus acidophilus*, *L. plantarum*, *L. rhamnosus*, and *L. reuteri* cell-free supernatants inhibit *Candida parapsilosis* pathogenic potential upon infection of vaginal epithelial cells monolayer and in a transwell coculture system *in vitro*. *Microbiol Spectr* 10:e02696-21. <https://doi.org/10.1128/spectrum.02696-21>.
47. MacAlpine J, Daniel-Ivad M, Liu Z, Yano J, Revie NM, Todd RT, Stogios PJ, Sanchez H, O'Meara TR, Tompkins TA, Savchenko A, Selmecki A, Veri AO, Andes DR, Fidel PL, Robbins N, Nodwell J, Whitesell L, Cowen LE. 2021. A small molecule produced by *Lactobacillus* species blocks *Candida albicans* filamentation by inhibiting a DYRK1-family kinase. *Nat Commun* 12:6151. <https://doi.org/10.1038/s41467-021-26390-w>.
48. Sant DG, Tupe SG, Ramana CV, Deshpande MV. 2016. Fungal cell membrane-promising drug target for antifungal therapy. *J Appl Microbiol* 121:1498–1510. <https://doi.org/10.1111/jam.13301>.
49. Suchodolski J, Muraszko J, Bernat P, Krasowska A. 2021. Lactate like fluconazole reduces ergosterol content in the plasma membrane and synergistically kills *Candida albicans*. *Int J Mol Sci* 22:5219. <https://doi.org/10.3390/ijms22105219>.
50. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. 2008. Genes and molecules of *Lactobacilli* supporting probiotic action. *Microbiol Mol Biol Rev* 72:728–764. <https://doi.org/10.1128/MMBR.00017-08>.
51. Pais P, Califormia R, Galocha M, Viana R, Ola M, Cavalheiro M, et al. 2020. *Candida glabrata* transcription factor *rpn4* mediates fluconazole resistance through regulation of ergosterol biosynthesis and plasma membrane permeability. *Antimicrob Agents Chemother* 64:e00554-20. <https://doi.org/10.1128/AAC.00554-20>.
52. Ang X, Mageswaran U, Chung Y, Lee B, Azhar S, Roslan N, Saufian IFB, Mustafa NS, Kalam EM, Ibrahim AF, Abdul Wahid N, Deris ZZ, Oon CE, Adnan WFW, Sany S, Liong MT. 2022. Probiotics reduce vaginal candidiasis in pregnant women via modulating abundance of *Candida* and *Lactobacillus* in vaginal and cervicovaginal regions. *Microorganisms* 10:285. <https://doi.org/10.3390/microorganisms10020285>.
53. Martinez RCR, Franceschini SA, Patta MC, Quintana SM, Candido RC, Ferreira JC, De Martinis ECP, Reid G. 2009. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic *Lactobacillus rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14. *Lett Appl Microbiol* 48:269–274. <https://doi.org/10.1111/j.1472-765X.2008.02477.x>.
54. Oliveira VMC, Santos SSF, Silva CRG, Jorge AOC, Leão MVP. 2016. *Lactobacillus* is able to alter the virulence and the sensitivity profile of *Candida albicans*. *J Appl Microbiol* 121:1737–1744. <https://doi.org/10.1111/jam.13289>.
55. Lourenço A, Pedro NA, Salazar SB, Mira NP. 2018. Effect of acetic acid and lactic acid at low pH in growth and azole resistance of *Candida albicans* and *Candida glabrata*. *Front Microbiol* 9:3265–3265. <https://doi.org/10.3389/fmicb.2018.03265>.
56. Zavrel M, Hoot SJ, White TC. 2013. Comparison of sterol import under aerobic and anaerobic conditions in three fungal species, *Candida albicans*, *Candida glabrata*, and *Saccharomyces cerevisiae*. *Eukaryot Cell* 12:725–738. <https://doi.org/10.1128/EC.00345-12>.
57. Nagi M, Tanabe K, Ueno K, Nakayama H, Aoyama T, Chibana H, Yamagoe S, Umeyama T, Oura T, Ohno H, Kajiwara S, Miyazaki Y. 2013. The *Candida glabrata* sterol scavenging mechanism, mediated by the ATP-binding cassette transporter *Aus1p*, is regulated by iron limitation: exogenous sterol uptake in *Candida glabrata*. *Mol Microbiol* 88:371–381. <https://doi.org/10.1111/mmi.12189>.
58. Okamoto M, Takahashi-Nakaguchi A, Tejima K, Sasamoto K, Yamaguchi M, Aoyama T, Nagi M, Tanabe K, Miyazaki Y, Nakayama H, Sasakawa C, Kajiwara S, Brown AJ, Teixeira MC, Chibana H. 2022. Erg25 controls host-cholesterol uptake mediated by *Aus1p*-associated sterol-rich membrane domains in *Candida glabrata*. *Front Cell Dev Biol* 10:820675. <https://doi.org/10.3389/fcell.2022.820675>.
59. Hosogaya N, Miyazaki T, Nagi M, Tanabe K, Minematsu A, Nagayoshi Y, Yamauchi S, Nakamura S, Imamura Y, Izumikawa K, Kakeya H, Yanagihara K, Miyazaki Y, Kugiyama K, Kohno S. 2013. The heme-binding protein Dap1 links iron homeostasis to azole resistance via the P450 protein *Erg11* in *Candida glabrata*. *FEMS Yeast Res* 13:411–421. <https://doi.org/10.1111/1567-1364.12043>.
60. Devaux F, Thiébaud A. 2019. The regulation of iron homeostasis in the fungal human pathogen *Candida glabrata*. *Microbiology (Reading)* 165:1041–1060. <https://doi.org/10.1099/mic.0.000807>.
61. Vyas VK, Bushkin GG, Bernstein DA, Getz MA, Sewastianik M, Barrasa MI, Bartel DP, Fink GR. 2018. New CRISPR mutagenesis strategies reveal variation in repair mechanisms among fungi. *mSphere* 3:e00154-18. <https://doi.org/10.1128/mSphere.00154-18>.

62. Istel F, Schwarzmüller T, Tscherner M, Kuchler K. 2015. Genetic transformation of *Candida glabrata* by heat shock. *Bio-Protoc* 5:e1529. <https://doi.org/10.21769/BioProtoc.1529>.
63. Labun K, Montague TG, Krause M, Torres Cleuren YN, Tjeldnes H, Valen E. 2019. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. *Nucleic Acids Res* 47:W171–W174. <https://doi.org/10.1093/nar/gkz365>.
64. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9:357–359. <https://doi.org/10.1038/nmeth.1923>.
65. Liao Y, Smyth GK, Shi W. 2019. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Res* 47:e47. <https://doi.org/10.1093/nar/gkz114>.
66. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15:550. <https://doi.org/10.1186/s13059-014-0550-8>.
67. Sae-Tun O, Maftukhah R, Noller C, Remlinger V, Meyer-Laker V, Sørensen A, et al. 2020. Comparison of commonly used extraction methods for ergosterol in soil samples. *Int Agrophysics* 34:425–432. <https://doi.org/10.31545/intagr/127707>.
68. Sprouffske K, Wagner A. 2016. Growthcurver: an R package for obtaining interpretable metrics from microbial growth curves. *BMC Bioinformatics* 17:172. <https://doi.org/10.1186/s12859-016-1016-7>.
69. R Core Team. 2020. R: a language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria. <https://www.r-project.org/>.
70. de Hoon MJL, Imoto S, Nolan J, Miyano S. 2004. Open source clustering software. *Bioinformatics* 20:1453–1454. <https://doi.org/10.1093/bioinformatics/bth078>.
71. Saldanha AJ. 2004. Java Treeview—extensible visualization of microarray data. *Bioinformatics* 20:3246–3248. <https://doi.org/10.1093/bioinformatics/bth349>.
72. Wickham H. 2016. ggplot2 elegant graphics for data analysis, 2nd ed. Springer, New York. <https://doi.org/10.1007/978-0-387-98141-3>.